These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
247 related items for PubMed ID: 33812206
1. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review. Hu T, Fang L, Shi L, Wang W, Huang Y. Am J Otolaryngol; 2021; 42(5):102973. PubMed ID: 33812206 [Abstract] [Full Text] [Related]
2. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials. Fang L, Shi L, Wang W, Hu T, Rao X. Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731 [Abstract] [Full Text] [Related]
5. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z, Cai Z, Cai Q, Hong Y, Zhang C, Huang K, Lin Z, Li M. Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [Abstract] [Full Text] [Related]
7. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C, Chen QY, Mai HQ. Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605 [Abstract] [Full Text] [Related]
9. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis. Bongiovanni A, Vagheggini A, Fausti V, Mercatali L, Calpona S, Di Menna G, Miserocchi G, Ibrahim T. Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249 [Abstract] [Full Text] [Related]
10. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z, Zhang Z, Luo J, Li N, Peng X. J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [Abstract] [Full Text] [Related]
11. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS, Tang LQ, Chen QY, Zhang L, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Wang L, Lv X, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. Oncotarget; 2016 May 17; 7(20):29739-48. PubMed ID: 27105538 [Abstract] [Full Text] [Related]
12. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Eur J Cancer; 2019 Sep 17; 119():87-96. PubMed ID: 31425966 [Abstract] [Full Text] [Related]
15. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. Ann Oncol; 2015 Jan 17; 26(1):205-211. PubMed ID: 25355717 [Abstract] [Full Text] [Related]
16. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies. Li M, Zhang B, Chen Q, Zhang L, Mo X, Chen Z, Jin Z, Chen L, You J, Zhang S. Head Neck; 2021 Jun 17; 43(6):1912-1927. PubMed ID: 33644916 [Abstract] [Full Text] [Related]
17. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis. Zhong Q, Luo D, Li X, Du Q, Liang Q, Liu W, Li J, Zhu X. Cancer Biol Ther; 2023 Dec 31; 24(1):2274121. PubMed ID: 37965924 [Abstract] [Full Text] [Related]
19. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Shen H, Yin J, Niu R, Lian Y, Huang Y, Tu C, Liu D, Wang X, Lan X, Yuan X, Zhang J. Radiother Oncol; 2022 Jun 31; 171():107-113. PubMed ID: 35461950 [Abstract] [Full Text] [Related]
20. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Liu L, Fei Z, Chen M, Zhao L, Su H, Gu D, Lin B, Cai X, Lu L, Gao M, Ye X, Jin X, Xie C. Radiat Oncol; 2018 Aug 13; 13(1):148. PubMed ID: 30103765 [Abstract] [Full Text] [Related] Page: [Next] [New Search]